An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome
- PMID: 35958430
- PMCID: PMC9360604
- DOI: 10.3389/fcvm.2022.916031
An intensive, structured, mobile devices-based healthcare intervention to optimize the lipid-lowering therapy improves lipid control after an acute coronary syndrome
Abstract
Aims: Despite the evidence, lipid-lowering treatment (LLT) in secondary prevention remains insufficient, and a low percentage of patients achieve the recommended LDL cholesterol (LDLc) levels by the guidelines. We aimed to evaluate the efficacy of an intensive, mobile devices-based healthcare lipid-lowering intervention after hospital discharge in patients hospitalized for acute coronary syndrome (ACS).
Methods and results: Ambiespective register in which a mobile devices-based healthcare intervention including periodic follow-up, serial lipid level controls, and optimization of lipid-lowering therapy, if appropriate, was assessed in terms of serum lipid-level control at 12 weeks after discharge. A total of 497 patients, of which 462 (93%) correctly adhered to the optimization protocol, were included in the analysis. At the end of the optimization period, 327 (70.7%) patients had LDLc levels ≤ 70 mg/dL. 40% of patients in the LDLc ≤ 70 mg/dL group were upgraded to very-high intensity lipid-lowering ability therapy vs. 60.7% in the LDLc > 70 mg/dL group, p < 0.001. Overall, 38.5% of patients had at least a change in their LLT. Side effects were relatively infrequent (10.7%). At 1-year follow-up, LDLc levels were measured by the primary care physician in 342 (68.8%) of the whole cohort of 497 patients. In this group, 71.1% of patients had LDLc levels ≤ 70 mg/dL.
Conclusion: An intensive, structured, mobile devices-based healthcare intervention after an ACS is associated with more than 70% of patients reaching the LDLc levels recommended by the clinical guidelines. In patients with LDLc measured at 1-year follow-up, 71.1% had LDLc levels ≤ 70 mg/dL.
Keywords: cardiovascular risk factors; ischemic heart disease; lipid-lowering therapy; mobile devices-based healthcare; secondary prevention.
Copyright © 2022 Ruiz-Bustillo, Badosa, Cabrera-Aguilera, Ivern, Llagostera, Mojón, Vicente, Ribas, Recasens, Martí-Almor, Cladellas and Farré.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
A new rational approach to reach LDL-cholesterol concentration objectives after an acute coronary syndrome.Clin Investig Arterioscler. 2019 May-Jun;31(3):93-100. doi: 10.1016/j.arteri.2018.11.004. Epub 2019 Jan 31. Clin Investig Arterioscler. 2019. PMID: 30711338 English, Spanish.
-
Efficacy of a nurse-led lipid-lowering secondary prevention intervention in patients hospitalized for ischemic heart disease: A pilot randomized controlled trial.Eur J Cardiovasc Nurs. 2019 Jun;18(5):366-374. doi: 10.1177/1474515119831511. Epub 2019 Feb 13. Eur J Cardiovasc Nurs. 2019. PMID: 30757908 Clinical Trial.
-
Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.Lipids Health Dis. 2016 Mar 12;15:55. doi: 10.1186/s12944-016-0227-2. Lipids Health Dis. 2016. PMID: 26968977 Free PMC article.
-
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.Curr Diab Rep. 2019 Nov 21;19(12):146. doi: 10.1007/s11892-019-1246-y. Curr Diab Rep. 2019. PMID: 31754844 Review.
-
2017 Taiwan lipid guidelines for high risk patients.J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24. J Formos Med Assoc. 2017. PMID: 28242176 Review.
Cited by
-
Learnings from Implementation Strategies to Improve Lipid Management.Curr Cardiol Rep. 2025 Jan 8;27(1):9. doi: 10.1007/s11886-024-02174-8. Curr Cardiol Rep. 2025. PMID: 39775142 Free PMC article. Review.
-
Opportunities and challenges of lifestyle intervention-based digital therapeutics in LDL-C management: a scoping review.Ther Adv Chronic Dis. 2025 May 14;16:20406223251334439. doi: 10.1177/20406223251334439. eCollection 2025. Ther Adv Chronic Dis. 2025. PMID: 40376548 Free PMC article.
References
-
- Wood DA, Kotseva K, Connolly S, Jennings C, Mead A. Euroaction Study Group et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet. (2008) 371:1999–2012. 10.1016/S0140-6736(08)60868-5 - DOI - PubMed
-
- Ribas N, García-García C, Meroño O, Recasens L, Pérez-Fernández S, Bazán V, et al. Secondary prevention strategies after an acute ST-segment elevation myocardial infarction in the AMI code era: beyond myocardial mechanical reperfusion. BMC Cardiovasc Disord. (2017) 17:54. 10.1186/s12872-017-0493-6 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources